Anne Li 6/30/2017 email@example.com
The molecular make-up of lung tumours could help identify patients who might benefit from immunotherapy treatment up front, a new study has found. The phase 3 clinical trial, run by The Ohio State University Comprehensive Cancer Center in the US, suggests that immunotherapy given before other drugs could improve the outlook for certain patients with advanced lung cancer. The findings are “an important step forward” in understanding which patients are likely to benefit from immunotherapy, said lead scientist Dr David Carbone.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-06-23-tumour-characteristics-could-predict-immunotherapy-success-in-lung-cancer